CIPLA LTD. - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Download	< Back
20 Feb 2025
Company has received final approval from USFDA for NDA submitted for Nilotinib Capsules 50, 150 and 200 mg on 19th February, 2025
View all announcements for CIPLA LTD.	Source: BSE India

Stocks	Mutual Funds		Investment tracking
A-Z Gainers - Daily \| Weekly \| Monthly Losers - Daily \| Weekly \| Monthly Group-wise listing IPO \| Top IPOs Recent IPOs \| IPO News Similar Price band Most traded - By volumes Top 100 - By market capitalisation Latest Company Results Management Speaks Market News	Top 25 schemes High-risk, High-returns Medium-risk, Medium-returns Low-risk, Low-returns Gilt Funds Funds of Funds Special Funds Liquid Funds Dynamic Asset Allocation NFOs MF Selector	Equity - ELSS Equity - Index Funds Equity - Sector Funds Equity - Balance Fund Equity - Diversified Fund MF News Budget 2025	My Portfolio My Watch List If You Had Invested... Global Indicators Forex Converter Market Indices Sectoral Indices World Indices Market Astrology Advertise with us

ALL MONEYWIZ PAGES